DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

Not Applicable

Completed

Conditions: Fatigue
Ovarian Cancer
Coping Skills
Coping Behavior

Interventions: Behavioral: REVITALIZE ACT Intervention
Behavioral: Enhanced Usual Care (EOC)

First Posted Date: 2020-08-25

Last Posted Date: 2024-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT04525183

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Phase 1

Completed

Conditions: Glioma, Malignant
Surgery
Seizures

Interventions: Drug: Standard of Care
Drug: Perampanel

First Posted Date: 2020-08-04

Last Posted Date: 2024-08-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT04497142

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

RESIST-ADT (Androgen Deprivation Therapy)

Not Applicable

Completed

Conditions: Prostate Cancer
Physical Function

Interventions: Behavioral: Progressive Resistance Training Exercise
Behavioral: Flexibility and Balance Exercise

First Posted Date: 2020-07-24

Last Posted Date: 2024-08-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT04485767

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

RCT of CBD for Anxiety in Advanced Breast Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Breast Cancer
Anxiety
CBD

Interventions: Other: Placebo
Drug: Cannabidiol

First Posted Date: 2020-07-22

Last Posted Date: 2024-10-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT04482244

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Intravenous Magnesium in Patients Receiving Cisplatin

Phase 1

Completed

Conditions: Mesothelioma

Interventions: Drug: Magnesium Sulfate

First Posted Date: 2020-07-22

Last Posted Date: 2022-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT04481672

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Phase 2

Active, not recruiting

Conditions: Skin Inflammation
Pediatric Cancer
CNS Tumor, Childhood

Interventions: Other: Warm Baths or Showers
Other: Moisturizer
Drug: SPF 30 or Higher Suncreen
Other: Sun Protective Clothing
Behavioral: Limited Sun Exposure
Other: Dilute bleach baths

First Posted Date: 2020-07-21

Last Posted Date: 2024-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04479514

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2

Recruiting

Conditions: Breast Cancer
Triple Negative Breast Cancer
PD-L1 Negative

Interventions: Drug: Sacituzumab Govitecan
Drug: Pembrolizumab

First Posted Date: 2020-07-13

Last Posted Date: 2024-04-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 110

Registration Number: NCT04468061

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Eastern Maine Medical Center, Brewer, Maine, United States

and more 7 locations

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2

Active, not recruiting

Conditions: Breast Cancer
Residual Cancer
Circulating Tumor DNA
Triple Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Sacituzumab govitecan

First Posted Date: 2020-06-16

Last Posted Date: 2024-10-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT04434040

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
University of Chicago Medical Center for Advanced Care Orland Park, Orland Park, Illinois, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 6 locations

MARGetuximab Or Trastuzumab (MARGOT)

Phase 2

Active, not recruiting

Conditions: HER2-positive Breast Cancer
Breast Cancer
Stage III Breast Cancer
Stage II Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Pertuzumab
Drug: Margetuximab
Drug: Trastuzumab

First Posted Date: 2020-06-11

Last Posted Date: 2024-10-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 174

Registration Number: NCT04425018

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana-Farber Brigham Cancer Center - Foxborough, Foxboro, Massachusetts, United States

and more 11 locations

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1

Recruiting

Conditions: Primary Central Nervous System Lymphoma
Refractory Cancer
Relapsed Cancer
Recurrent Cancer

Interventions: Drug: Ibrutinib
Drug: Pembrolizumab
Drug: Rituximab

First Posted Date: 2020-06-09

Last Posted Date: 2024-10-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT04421560

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy